Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

2019-nCoV

- PMLiVE

WHO releases largest global collection of publicly available health inequality data

The repository is composed of nearly 11 million data points across more than 2,000 indicators

- PMLiVE

Gilead’s COVID-19 treatment shows promising results in vulnerable patient populations

Veklury demonstrated a reduction in mortality and hospital readmission rates

- PMLiVE

BioNTech reveals plans to spend about €1bn more on research and development this year

The company has already started clinical trials assessing four new infectious disease vaccines

- PMLiVE

WHO report highlights impact of COVID-19 pandemic on non-communicable diseases

These diseases were responsible for an estimated 40 million of all deaths globally in 2019

- PMLiVE

Pfizer/BioNTech’s Omicron-adapted booster approved by FDA for young children

The companies have also submitted an application to the EMA for this age group

- PMLiVE

JCVI recommends spring COVID-19 booster for those at highest risk

Eligible individuals will be offered the booster around six months after their previous dose

- PMLiVE

WHO countries begin negotiations on global pandemic preparedness agreement

The discussions will continue over the next year until a final draft is made in 2024

- PMLiVE

Pfizer/BioNTech submit FDA application for Omicron-adapted booster for young children

The vaccine is already authorised as the third of a three-dose primary series in this age group

- PMLiVE

WHO announces recommended 2023-24 flu vaccines for northern hemisphere

The constantly evolving nature of influenza viruses requires frequent reformulation of vaccines

- PMLiVE

WHO and ESCEO partner to develop roadmap for bone health and ageing

Over 1.7 billion people globally live with musculoskeletal conditions

- PMLiVE

Gilead reports positive real-world evidence for COVID-19 treatment Veklury

A study of more than 500,000 hospitalised patients showed a reduction in mortality risk

- PMLiVE

Merck and Ridgeback’s COVID-19 pill fails to prevent infection within households

Lagevrio is already approved to treat certain patients with COVID-19 in several markets

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links